The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Correspondence
PreviousPrevious
Volume 358:1517-1518 April 3, 2008 Number 14
NextNext

Telbivudine versus Lamivudine in Patients with Chronic Hepatitis B

Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

 Sign up for free e-toc
 

This Article
-Full Text
- PDF
-PDA Full Text
-Purchase this article

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited
-E-mail When Letters Appear

More Information
-Related Article
by Lai, C.-L.
-PubMed Citation
To the Editor: We would like to raise four points with respect to the report by Lai et al. (Dec. 20, 2007, issue)1 on the 1-year results of their study comparing telbivudine with lamivudine in patients with hepatitis B virus (HBV) infection. First, the authors elucidate the role of the viral load at week 24 as a predictor for response and resistance. A decrease in the HBV viral load below 1000 copies per milliliter at week 12 has been reported to correlate with response and absence of resistance.2 More recently, a "week-4 prediction" was suggested for a viral-load decrease below . . . [Full Text of this Article]



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.